85 related articles for article (PubMed ID: 11127939)
1. Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer.
Sengeløv L; Kamby C; Geertsen P; Andersen LJ; von der Maase H
Cancer Chemother Pharmacol; 2000; 46(5):357-64. PubMed ID: 11127939
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy.
Jessen C; Agerbaek M; Von Der Maase H
Acta Oncol; 2009; 48(3):411-7. PubMed ID: 18798018
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens.
Lin CC; Hsu CH; Huang CY; Tsai YC; Huang KH; Cheng AL; Pu YS
Urology; 2007 Mar; 69(3):479-84. PubMed ID: 17382149
[TBL] [Abstract][Full Text] [Related]
4. The impact of gender on outcomes in patients with metastatic urothelial carcinoma.
Haines L; Bamias A; Krege S; Lin CC; Hahn N; Ecke TH; Moshier E; Sonpavde G; Godbold J; Oh WK; Galsky MD
Clin Genitourin Cancer; 2013 Sep; 11(3):346-52. PubMed ID: 23673281
[TBL] [Abstract][Full Text] [Related]
5. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.
Galsky MD; Moshier E; Krege S; Lin CC; Hahn N; Ecke T; Sonpavde G; Godbold J; Oh WK; Bamias A
Cancer; 2013 Aug; 119(16):3012-9. PubMed ID: 23720216
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy.
Kim JG; Ryoo BY; Park YH; Kim BS; Kim TY; Im YH; Kang YK
Cancer Chemother Pharmacol; 2008 Feb; 61(2):301-7. PubMed ID: 17429626
[TBL] [Abstract][Full Text] [Related]
7. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.
Galsky MD; Moshier E; Krege S; Lin CC; Hahn N; Ecke T; Sonpavde G; Pond G; Godbold J; Oh WK; Bamias A
Urol Oncol; 2014 Jan; 32(1):48.e1-8. PubMed ID: 24055428
[TBL] [Abstract][Full Text] [Related]
8. Impact of multimodal treatment on survival in patients with metastatic urothelial cancer.
Abe T; Shinohara N; Harabayashi T; Sazawa A; Maruyama S; Suzuki S; Nonomura K
Eur Urol; 2007 Oct; 52(4):1106-13. PubMed ID: 17367917
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer.
Galsky MD; Krege S; Lin CC; Hahn N; Ecke TH; Moshier E; Sonpavde G; Godbold J; Oh WK; Bamias A
Urol Oncol; 2014 Jan; 32(1):30.e15-21. PubMed ID: 23428534
[TBL] [Abstract][Full Text] [Related]
10. Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy.
Recondo G; Armand JP; Tellez-Bernal E; Domenge C; Belehradek M; De Vathaire F; Wibault P; Richard JM; Cvitkovic E
Laryngoscope; 1991 May; 101(5):494-501. PubMed ID: 1709437
[TBL] [Abstract][Full Text] [Related]
11. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.
Pond GR; Bellmunt J; Fougeray R; Choueiri TK; Qu AQ; Niegisch G; Albers P; Di Lorenzo G; Salhi Y; Galsky MD; Agarwal N; Necchi A; Sonpavde G
Clin Genitourin Cancer; 2013 Dec; 11(4):495-500. PubMed ID: 23800847
[TBL] [Abstract][Full Text] [Related]
12. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma.
Siu LL; Banerjee D; Khurana RJ; Pan X; Pflueger R; Tannock IF; Moore MJ
Clin Cancer Res; 1998 Mar; 4(3):559-65. PubMed ID: 9533522
[TBL] [Abstract][Full Text] [Related]
13. [Results of long-term treatment of inoperable cancer of the bladder with cisplatin and concurrent irradiation: prognostic factors of local control and survival].
Chauvet B; Félix-Faure C; Davin JL; Choquenet C; Alfonsi M; Reboul F
Cancer Radiother; 1998 Apr; 2 Suppl 1():85s-91s. PubMed ID: 9749086
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.
Bamias A; Aravantinos G; Deliveliotis C; Bafaloukos D; Kalofonos C; Xiros N; Zervas A; Mitropoulos D; Samantas E; Pectasides D; Papakostas P; Gika D; Kourousis C; Koutras A; Papadimitriou C; Bamias C; Kosmidis P; Dimopoulos MA;
J Clin Oncol; 2004 Jan; 22(2):220-8. PubMed ID: 14665607
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Kim WK; Lee JS; Kang YK
Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report.
Takahashi S; Suzuki M; Kume H; Matsumoto S; Okamoto N; Nishimatsu H; Tomita K; Kitamura T
Jpn J Clin Oncol; 2005 Feb; 35(2):79-83. PubMed ID: 15709091
[TBL] [Abstract][Full Text] [Related]
17. Prognostic model to predict survival in patients with metastatic upper tract urothelial carcinoma treated with cisplatin-based chemotherapy.
Hsieh MC; Su YL; Chiang PH; Rau KM; Chen YY; Huang CH
Int J Urol; 2016 May; 23(5):385-9. PubMed ID: 26992082
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.
Argiris A; Li Y; Forastiere A
Cancer; 2004 Nov; 101(10):2222-9. PubMed ID: 15452834
[TBL] [Abstract][Full Text] [Related]
19. [Effects of pre-chemotherapy hemoglobin and platelet levels in patients with stage Ib2-IIb cervical cancer treated with neoadjuvant chemotherapy followed by radical hysterectomy].
Wang D; Wu M; Ren T; Wan XR; Feng FZ; Huang HF; Yang JX; Shen K; Xiang Y
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):577-81. PubMed ID: 23141176
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for metastatic urothelial carcinoma undergoing cisplatin-based salvage chemotherapy.
Taguchi S; Nakagawa T; Hattori M; Niimi A; Nagata M; Kawai T; Fukuhara H; Nishimatsu H; Ishikawa A; Kume H; Homma Y
Jpn J Clin Oncol; 2013 Sep; 43(9):923-8. PubMed ID: 23888082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
